[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-open-angle-glaucoma-poag\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-open-angle-glaucoma-poag":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,71,95,127,156,186,210,242,265,289,314,339,370],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100644992","phase-1-regn22530-for-adults-with-primary-open-angle-glaucoma-or-ocular-hypertension-100644992",false,"NCT07675824","REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension","A Phase 1\u002F2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular Hypertension","BAHAMA","Key Inclusion Criteria:\n\n1. Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol\n2. Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to 20\u002F200) in the study eye on day 1\n3. BCVA of ≥55 EDTRS letters (Snellen equivalent of better than or equal to 20\u002F80) in the non-study eye on day 1\n4. Phakic or pseudophakic with a posterior chamber intraocular lens that has been implanted ≥3 months prior to Screening Visit 1\n5. Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality posterior segment imaging in the study eye\n\nKey Exclusion Criteria:\n\nOcular-specific exclusion criteria apply to the Study Eye only, unless otherwise specified.\n\n1. OAG or OHT secondary to pigment dispersion, pseudoexfoliation, trauma, uveitis, neovascularization, a vascular disorder, or steroid use\n2. Congenital or traumatic cataract, or visually significant cataract that is likely to require surgical intervention during the study\n3. Presence of significant corneal scarring or irregularities that could interfere with reliable IOP measurement\n4. Prior incisional or bleb-forming glaucoma surgery, suprachoroidal procedures, Trabecular Meshwork (TM)-stripping Microinvasive Glaucoma Surgery (MIGS), angle-based implants other than iStent or iridectomy\u002Firidotomy as described in the protocol\n5. History of Selective Laser Trabeculoplasty (SLT) within 6 months prior to day 1\n6. History of transscleral (including micropulse) or endoscopic cyclophotocoagulation within 1 year prior to day 1\n\nNote: Other protocol defined Inclusion\u002F Exclusion criteria apply","ALL","18 Years",{"count":20,"type":21},271,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study will test an experimental drug called REGN22530 (\"study drug\") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP).\n\nREGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure.\n\nThe study is looking at:\n\n* What side effects REGN22530 might cause\n* How much REGN22530 is in the blood and eye fluid at different times\n* If the body has any reactions to REGN22530 (which may cause REGN22530 to not work as well)\n* How the body and eye pressure respond after having REGN22530, which can help researchers understand why REGN22530 works better in some people than others\n* How well REGN22530 works",[28,29],"Primary Open Angle Glaucoma (POAG)","Ocular Hypertension (OHT)",[31,32,33],"Intraocular Pressure (IOP)","First in Human (FIH)","Open Angle Glaucoma (OAG)","NOT_YET_RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":21},"2026-07-23",{"date":42,"type":21},"2029-10-16",{"name":44,"class":45},"Regeneron Pharmaceuticals","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100641250","phase-3-a-comparative-randomized-investigator-blind-active-controlled-parallel-group-multicenter-clinical-endpoint-study-100641250","NCT07661329","A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study","A Comparative Randomized, Investigator-Blind, Active-Controlled, Parallel-Group, Multicenter, Clinical Endpoint Study to Evaluate Efficacy and Safety of Bimatoprost Ophthalmic Solution 0.01% (YSBP) of YS Life Science Co., Ltd. (YSLS) and Lumigan® (Bimatoprost Ophthalmic Solution) 0.01% of AbbVie INC, in the Treatment of Subjects With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH).","Inclusion Criteria:\n\n* Subjects willing and able to provide voluntary informed consent and to follow protocol requirements.\n* Male or females aged ≥18 years.\n* Subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) in both eyes\n* Subjects requiring treatment in both the eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.\n* Adequate washout period prior to baseline (Day 0) of any ocular hypotensive medications\n* Baseline (Day 0\u002Fhour 0) IOP ≥22 mm Hg and ≤ 34 mm Hg in both eyes, with difference between the IOP in left and right eyes not being more than 5 mm Hg\n* Subjects' IOP is likely to be controlled with monotherapy.\n* Baseline best corrected visual acuity equivalent to Snellen acuity of 20\u002F100 or better in each eye, using a logarithmic visual acuity chart.\n* Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the study participation) practicing any of the following acceptable methods of contraception:\n\n  1. Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication.\n  2. Intrauterine device (IUD) or intrauterine system (IUS)\n  3. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)\n  4. Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)\n  5. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation\n  6. Total abstinence; partial abstinence is not acceptable\n* No history of addiction to any recreational drug or drug dependence or alcohol addiction\n\nExclusion Criteria:\n\n* Female subjects with positive pregnancy test or lactating or planning a pregnancy.\n* Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation or benzalkonium chloride.\n* Current or history of severe hepatic or renal impairment.\n* Current or history within 3 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts will be allowed provided that the other inclusion\u002Fexclusion criteria are met).\n* Current corneal abnormalities that would prevent accurate IOP readings with tonometer.\n* Functionally significant visual field loss as determined by perimetry.\n* Subjects with corneal grafts.\n* Subject has contraindication to pupil dilation.\n* Use at any time prior to baseline of an intraocular corticosteroid implant.\n* Use of contact lens within 1 week prior to baseline.\n* Use within 21 days prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid.\n* Use within 21 days prior to baseline of a systemic corticosteroid.\n* Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid.\n* Underwent within 3 months prior to baseline any other intraocular surgery (e.g., cataract surgery).\n\nUnderwent any filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty) within 3 months prior to baseline or refractive surgery at any time.\n\n* Subjects with a history of non-responder to bimatoprost monotherapy.\n* Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination.\n* Severe glaucoma with a cup\u002Fdisk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion).\n* Chronic use of any systemic medication that may affect IOP with less than 2 months stable dosing regimen (i.e., sympathomimetic agents, betaadrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.)\n* Central Corneal thickness (CCT) \\\u003C480 microns or \\>620 microns for study eye.\n* Known history or presence of any uncontrolled systemic disease\n* History of recurrent ocular seasonal allergies within past 2 years prior to screening.\n* Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements.\n* Participation in any clinical study within 30 days before the first dose of the study drug.\n* Subjects with known cases of active Hepatitis B virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection.\n* Subjects with aphakia or history of herpes simplex keratitis",{"count":54,"type":21},600,[56],"PHASE3","This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.",[28,59],"Ocular Hypertension (OH)","RECRUITING","2026-06-16",{"date":63,"type":38},"2026-06-22",{"date":65,"type":38},"2026-06-02",{"date":67,"type":21},"2027-12-31",{"name":69,"class":45},"YS Life Science Co., Ltd.",16,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100625147","comparison-of-goniotomy-device-outcomes-in-combined-phacoemulsification-goniotomy-surgeries-100625147","NCT07418853","Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries","Inclusion Criteria: Adults ≥ 18 years old\n\n* Diagnosed with primary or secondary open-angle glaucoma (e.g., POAG, pigmentary, pseudoexfoliative)\n* Scheduled for phacoemulsification with planned goniotomy\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Angle-closure glaucoma\n\n  * Prior glaucoma surgery in the study eye\n  * Planned stand-alone goniotomy\n  * Inability to comply with follow-up schedule",{"count":78,"type":21},132,[80],"NA","The goal of this study is to determine of one of three different devices to perform goniotomy to treat glaucoma at the time of cataract surgery is more or less effective than the others. The primary outcomes are to compare intraocular pressure control and glaucoma medication use up to 6 months after surgery. Participants will under combined cataract surgery and goniotomy. They will have post-operative follow up visits at 1 day, 1 week, 1 month, 3 months, and 6 month",[33,28,83],"Secondary Open Angle Glaucoma","2026-06-09",{"date":86,"type":38},"2026-06-11",{"date":88,"type":21},"2026-07-01",{"date":90,"type":21},"2028-03-01",{"name":92,"class":93},"Henry Ford Health System","OTHER",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":94},"100586894","phase-1-gvb-2001-gene-therapy-via-intracameral-injection-for-the-treatment-of-primary-open-angle-glaucoma-100586894","NCT06921317","GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma","Proof of Concept Clinical Trial of Gene Therapy GVB-2001 Delivered Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma","Inclusion Criteria:\n\n1. The subjects volunteered to participate in the clinical study and signed written informed consent;\n2. Aged 18 to 75 years old (inclusive), men and women;\n3. Primary open angle glaucoma (POAG) with a history of diagnosis ≥1 year;\n4. Participants in good general health and have no clinically significant systemic disease, as determined by medical history, physical examination, and screening laboratory evaluation.\n5. To comply with the requirements, willing to accept all the diagnosis and treatment plan, laboratory tests and other specified testing, etc.;\n6. Consent is obtained for an extended safety visit after 1 year.\n\nSpecial eligibility criteria for trial group 1:\n\n1. no vision in the target eye;\n2. The intraocular pressure (IOP) of the target eye was ≤50mmHg and \\> 21 mmHg after combined treatment with 2 or more IOP-lowering drugs.\n\nSpecial inclusion criteria for trial group 2:\n\n1. The intraocular pressure (IOP) of the target intervention eye was no more than 40mmHg, and the IOP was more than 21 mmHg after receiving combination therapy of 2 or more IOP-lowering drugs;\n2. The Shaffer gonioscopy scores of the target intervention eyes were all greater than 3.\n3. The best corrected distance visual acuity of the target intervention eyes was at least 0.3 (logMAR4.5) and above.\n\nExclusion Criteria:\n\n1. Secondary glaucoma;\n2. Any active or recurrent intraocular infection or inflammation, including but not limited to uveitis;\n3. Severe dry eye or clinically significant active keratopathy in the target eye;\n4. No intraocular pressure measurement was performed under any circumstances;\n5. Allergies to drugs or their excipient to be used in clinical studies;\n6. Ocular trauma in either eye within 6 months before screening, or eye surgery or nonrefractive laser therapy within 3 months before screening;\n7. A clinically significant history of herpes simplex or herpes zoster keratitis;\n8. A positive test for hepatitis B virus (HBV) HBsAg or HBV-DNA, hepatitis C virus (HCV) HCAb, or Epstein-Barr virus, or cytomegalovirus (CMV);\n9. Syphilis antibody and HIV antibody were positive.\n10. Severe active systemic bacterial, viral, fungal, malaria, or parasitic infections;\n11. Any past or present malignant tumor, myeloproliferative disorder or immunodeficiency disease;\n12. May interfere with the clinical significance of this study of systemic disease (including, active hepatitis, liver cirrhosis, liver fibrosis uncontrolled hypertension, myocardial infarction and myocarditis, arrhythmia, stroke, acute or chronic renal insufficiency, uncontrolled endocrine system diseases such as diabetes, thyroid function hyperfunction, Severe pulmonary hypertension, chronic obstructive pulmonary disease (copd), interstitial pneumonia, etc.);\n13. Any serious mental illness;\n14. Have participated in other clinical trials and received a medication or medical device intervention within 1 month before screening;\n15. And women of childbearing age who are pregnant, breastfeeding, planning to become pregnant, or who are not using a medically acceptable form of birth control. Excludes women of childbearing age who have been sterilized for 1 year after menopause or 3 months after surgery;\n16. Other subjects judged by the clinical investigator to be ineligible for inclusion.\n\nSpecial Exclusion Criteria for trial group 1:\n\n1\\) The serum Anti-AAV2 neutralizing antibody titer was \\> 1:200 at the time of screening.\n\nSpecial Exclusion Criteria for trial group 2:\n\n1. Retinal diseases that might have interfering with the study: quadrantinal blindness of unknown cause, wet age-related macular degeneration, retinal vein occlusion, cystoid macular edema, macular hole, maculopathy with neovascularization, and central serous retinopathy;\n2. Narrow anterior chamber Angle, congenital Angle closure glaucoma or room, clinically significant peripheral anterior chamber adhesion or anterior chamber Angle surgery\u002Flaser treatment cause extensive catarrhal adhesion of history;\n3. The central corneal thickness was less than 480μm or more than 620μm.\n4. Presence of severe visual field impairment (e.g., mean deviation less than -12 dB or mean visual field defect greater than 2 dB\u002F year, as assessed by a perimetry analyzer)\n5. The target eye had undergone intraocular anti-glaucoma surgery or anti- glaucoma laser surgery;\n6. The serum Anti-AAV2 neutralizing antibody titer was \\> 1:400 at the time of screening.","75 Years",{"count":104,"type":21},6,[24,25],"This is an investigator initiated, single center, open label, non-randomized, exploratory clinical study. The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via intracameral injection to the anterior segment of the eye for the treatment of subjects with primary open-angle glaucoma. At least 6 primary open angle glaucoma (POAG) patients with high intraocular pressure (IOP) will be divided into two experimental groups. The first subject was given low-dose treatment, and the follow-up subjects were determined by the Safety Review Committee (SRC). Each experimental group was given low-dose and high-dose drug treatment respectively, and low-dose or high-dose treatment was given. The optimal dose will be selected based on the trial results for future development of GVB-2001.\n\nSafety Review Committee, SRC will be set up for safety assessment of the study. The study subjects included will be 18 to 75 years of age (inclusion) and are diagnosed with primary open-angle glaucoma (POAG) for 1 year or more. Only participants who provide informed consent prior to all screening procedures will be eligible for enrollment into the trial.",[108],"Primary Open-Angle Glaucoma (POAG)",[110,111,112,113,114,115,116,117],"glaucoma","gene therapy","rho gene","trabecular meshwork","dnRhoA","IOP reduction","AAV","scAAV","2026-04-28",{"date":120,"type":38},"2026-05-04",{"date":122,"type":38},"2025-11-19",{"date":124,"type":21},"2028-02-28",{"name":126,"class":45},"IVIEW Therapeutics Inc.",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100629892","personalized-mobile-reminders-for-medication-adherence-and-intraocular-pressure-control-in-primary-open-angle-glaucoma-100629892","NCT07480577","Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma","Effectiveness of a Personalized Mobile Reminder System on Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma: A Prospective, Parallel-Group, Randomized Controlled Trial","M-GLAUCO","Inclusion Criteria:\n\nAdults aged 18 to 75 years. Diagnosis of primary open-angle glaucoma (POAG) in at least one eye. Currently treated with at least one topical antiglaucoma medication. Able to read and understand study procedures and provide written informed consent.\n\nHas regular access to a mobile phone capable of receiving SMS or WhatsApp messages.\n\nWilling to comply with follow-up visits and study procedures for 3 month\n\nExclusion Criteria:\n\nSecondary glaucoma (e.g., neovascular, uveitic, steroid-induced) or angle-closure glaucoma.\n\nOcular surgery or laser procedure within the previous 3 months, or planned ocular surgery during study follow-up.\n\nAdvanced ocular comorbidity likely to affect IOP assessment or adherence evaluation (e.g., severe corneal disease, active ocular infection\u002Finflammation).\n\nCognitive impairment, severe psychiatric disease, or communication barriers that prevent reliable participation.\n\nInability to use or access mobile messaging tools required for the intervention.\n\nParticipation in another interventional clinical study that may interfere with outcomes",{"count":136,"type":21},84,[80],"This study evaluates whether a personalized mobile reminder program improves treatment adherence and clinical outcomes in adults with primary open-angle glaucoma (POAG) using topical antiglaucoma eye drops. Poor adherence to long-term eye-drop therapy is common in glaucoma care and may contribute to inadequate intraocular pressure (IOP) control and disease progression.\n\nParticipants are randomized to either (1) a digital adherence intervention or (2) standard outpatient follow-up. The intervention consists of daily interactive SMS\u002FWhatsApp medication reminders plus weekly brief educational messages for 3 months. The primary outcome is change in medication adherence measured by the Morisky Medication Adherence Scale-8 (MMAS-8) at month 3. Secondary outcomes include change in IOP, eye-drop instillation technique, and treatment satisfaction. Exploratory analyses assess the relationship between adherence level and OCT-based retinal nerve fiber layer (RNFL) progression metrics. The goal is to determine whether a low-cost, scalable mobile strategy can improve short-term glaucoma management in routine practice.",[108],[141,142,143,144,145,146],"Primary Open-Angle Glaucoma","Medication Adherence","Mobile Reminder","SMS Reminder","WhatsApp Reminder","MMAS-8","2026-03-14",{"date":149,"type":38},"2026-03-18",{"date":151,"type":21},"2026-04-01",{"date":153,"type":21},"2026-08-01",{"name":155,"class":93},"Sakarya Yenikent State Hospital",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100628466","aqueous-humor-and-ocular-tissue-analysis-in-glaucoma-and-cataract-100628466","NCT07462000","Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract","Integrated Chemical and Proteomic Analysis of Aqueous Humor and Ocular Tissues in Glaucoma and Cataract Patients","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Scheduled for cataract surgery (phacoemulsification with intraocular lens implantation).\n* Ability to provide written informed consent.\n* For glaucoma arm: diagnosis of primary open-angle glaucoma (POAG) with coexisting cataract, and planned combined cataract surgery with glaucoma procedure.\n* For control arm: cataract without glaucoma and without other significant ocular pathology.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Pregnancy or breastfeeding.\n* Advanced visual impairment in the study eye (visual aquity worse than counting fingers).\n* Any glaucoma type other than primary open-angle glaucoma (e.g., angle-closure, secondary, neovascular glaucoma).\n* History of intraocular surgery in the study eye (including glaucoma surgery), vitreoretinal surgery, corneal transplantation, or refractive surgery.\n* Active or previous uveitis.\n* Other significant chronic ocular disease in the study eye (other than cataract and POAG in the glaucoma arm).\n* Inability to comply with study procedures or follow-up visits.",{"count":164,"type":21},40,[80],"This observational study will compare proteomic and elemental profiles of aqueous humor and ocular tissues in patients with primary open-angle glaucoma (POAG) and cataract versus cataract controls without glaucoma. Samples collected during standard surgery will be analyzed using LC-MS\u002FMS and ICP-MS. The goal is to identify glaucoma-associated molecular patterns with potential diagnostic or prognostic relevance.",[108,168],"Cataract",[170,171,168,141,172,173,174,175],"POAG","Glaucoma","Proteomics","Aqueous Humor","LC-MS\u002FMS","Deep Sclerectomy","2026-03-06",{"date":178,"type":38},"2026-03-10",{"date":180,"type":38},"2026-01-21",{"date":182,"type":21},"2027-11-30",{"name":184,"class":93},"Military Institute od Medicine National Research Institute",2,{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":94},"100627885","ubm-evaluation-after-combined-deep-sclerectomy-with-trabeculotomy-in-primary-open-angle-glaucoma-100627885","NCT07454447","UBM Evaluation After Combined Deep Sclerectomy With Trabeculotomy in Primary Open Angle Glaucoma","Ultrasound Biomicroscopy Evaluation After Combined Deep Sclerectomy With Trabeculotomy in Primary Open Angle Glaucoma","Inclusion Criteria:\n\n* Diagnosis of primary open-angle glaucoma (POAG), including juvenile open-angle glaucoma (JOAG).\n* Patients who underwent combined deep sclerectomy with trabeculotomy.\n* Clear media allowing adequate ultrasound biomicroscopy imaging.\n* Written informed consent obtained from the patient .\n\nExclusion Criteria:\n\n* Secondary glaucomas (e.g., neovascular, uveitic, traumatic, or angle-closure glaucoma).\n* Previous glaucoma filtering surgery in the studied eye.\n* Coexisting ocular pathology affecting UBM assessment (e.g., severe corneal opacity, scleral pathology).",{"count":194,"type":21},30,"OBSERVATIONAL","Primary open-angle glaucoma is a chronic optic neuropathy that often requires surgical intervention when medical treatment fails. Deep sclerectomy is a non-penetrating glaucoma surgery that aims to reduce intraocular pressure while minimizing complications. When combined with trabeculotomy, additional aqueous outflow may be achieved.\n\nUltrasound biomicroscopy (UBM) allows detailed imaging of the anterior segment and provides valuable information about postoperative anatomical changes that cannot be assessed clinically. This observational study aims to evaluate UBM findings after combined deep sclerectomy with trabeculotomy in patients with primary open-angle glaucoma and to correlate these findings with clinical outcomes.",[28],[199,175,200,201],"Primary Open Angle Glaucoma","Trabeculotomy","Ultrasoun Biomicroscopy","2026-03-03",{"date":176,"type":38},{"date":205,"type":38},"2025-11-11",{"date":207,"type":21},"2026-12",{"name":209,"class":93},"Minia University Hospital",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":218,"maxAge":102,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":185},"100617772","evaluation-of-brudyglauco-dha--citicoline-in-patients-with-glaucoma-100617772","NCT07322965","Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma","Evaluation of the Effect of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma","BRUDYGLAUCO","Inclusion Criteria:\n\n1. Patients with chronic glaucoma (primary or secondary, open-angle or closed-angle) diagnosed in at least one eye, meeting the following criteria:\n\n   Structural damage: Thinning of the neuroretinal rim, peripapillary hemorrhage, or reduction in the nerve fiber layer, confirmed by OCT or color fundus photography.\n\n   Functional damage: At least 3 contiguous abnormal points outside the 95% confidence limit in the pattern deviation map of the visual field.\n2. At least 4 reliable visual field (VF) tests before study enrollment.\n3. Age between 50 and 75 years.\n4. If both eyes meet the inclusion criteria, the eye with the worst Mean Deviation (MD) will be selected as the study eye.\n\nExclusion Criteria:\n\n1. Use of any vitamin or nutraceutical supplement in the month prior to screening.\n2. Any condition that could alter visual field testing, including:\n\n   Neurological diseases. Retinal diseases. Advanced cataracts. Treatment with Lyrica (Pregabalin) due to its effect on visual fields.\n3. Hypersensitivity to acetylsalicylic acid (aspirin) (cross-reactivity risk with citicoline).\n4. Ocular surgery or laser treatment in the 3 months prior to enrollment or planned during the study.\n5. Mean Deviation (MD) of the visual field worse than -20 dB or better than -3 dB.","50 Years",{"count":220,"type":21},108,[80],"This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial.\n\nThis is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence.\n\nThe trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function.\n\nThe results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.",[171,28,224],"Neuroprotection",[110,108,224,226,227,228,229,230,231,232],"Visual Field","DHA (Docosahexaenoic Acid)","Citicoline","Nutritional Supplement","Clinical Trial","Randomized Controlled Trial (RCT)","Visual Function","2026-01-12",{"date":235,"type":38},"2026-01-14",{"date":237,"type":38},"2025-04-01",{"date":239,"type":21},"2027-05-30",{"name":241,"class":93},"Institut Catala de Retina",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":249,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":94},"100618714","phase-3-efficacy-and-safety-of-huc3-637-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-100618714","NCT07335211","Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n* Adults aged 19 years and older\n* Participants diagnosed with POAG or OH\n* Have fully explained and understood the study and have voluntarily given written informed consent.\n\nExclusion Criteria:\n\n* Acute or chronic angle-closure glaucoma\n* Congenital glaucoma, secondary glaucoma (open-angle glaucoma)","19 Years",{"count":251,"type":21},206,[56],"A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension",[28,255],"Ocular Hypertension","2026-01-11",{"date":258,"type":38},"2026-01-13",{"date":260,"type":21},"2026-01",{"date":262,"type":21},"2027-12",{"name":264,"class":45},"Huons Co., Ltd.",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":94},"100604294","direct-selective-laser-trabeculoplasty-dslt-for-reducing-eye-pressure-in-non-caucasian-patients-with-open-angle-glaucoma-100604294","NCT07147647","Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma","Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Non-Caucasian Open Angle Glaucoma Patients","Inclusion Criteria:\n\n* Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes.\n* Diagnosis of mild to moderate primary open angle glaucoma (POAG).\n* Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system.\n* Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg.\n\nExclusion Criteria:\n\n* Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0).\n* Previous glaucoma surgeries\u002Finterventions:\n* Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).\n* Secondary glaucoma:\n* Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.\n* Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.\n* Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry.",{"count":273,"type":21},60,[80],"The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma. The main question it aims to answer is:\n\nWhat is the washed out eye pressure (eye pressure when not on any glaucoma medications) of participants 6 months after the Direct Selective Laser Trabeculoplasty (DSLT) procedure compared to the washed out eye pressure of participants prior to the DSLT procedure.\n\nParticipants will:\n\nUndergo the DSLT procedure in one or both eyes and visit the clinic 1 month, 3 months, and 6 months after the procedure to have their vision and eye pressure measured.",[28],[278,279,199,170,171],"Direct Selective Laser Trabeculoplasty","DSLT","2025-08-22",{"date":282,"type":38},"2025-08-29",{"date":284,"type":38},"2025-07-16",{"date":286,"type":21},"2026-10",{"name":288,"class":45},"Select Eye Care",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":295,"sex":17,"minAge":296,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":94},"100602161","association-between-matrix-metalloproteinase-9-gene-polymorphism-and-susceptibility-to-primary-open-angle-glaucoma-patients-in-sohag-university-hospital-100602161","NCT07119905","Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital","Inclusion Criteria:\n\n* Men and women older than 30 years\n* Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)\n* Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)\n\nExclusion Criteria:\n\n* Exfoliation glaucoma, pigmentary glaucoma\n* History of acute angle closure",true,"30 Years",{"count":298,"type":21},80,"The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to",[28],[199,170,302,303,304],"Gene Polymorphism","MMP-9","Matrix Metalloproteinase-9 Gene Polymorphism","2025-08-06",{"date":307,"type":38},"2025-08-13",{"date":309,"type":21},"2026-06-01",{"date":311,"type":21},"2027-02-01",{"name":313,"class":93},"Sohag University",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":322,"maxAge":4,"enrollmentInfo":323,"targetDuration":325,"studyType":195,"phases":4,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":337,"locationsCount":185},"100563399","a-real-world-evidence-study-of-goniotomy-with-the-c-rex-instrument-in-patients-with-primary-open-angle-glaucoma-100563399","NCT06615661","A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma","An Observational Real-World Evidence Study of Ab-Interno Goniotomy Performed Using the C-Rex Instrument in Patients With Primary Open Angle Glaucoma","CIRCLE","Inclusion Criteria:\n\n* Primary open angle glaucoma\n* Goniotomy surgery performed using the C-Rex Instrument\n\nExclusion Criteria:\n\n* History of intraocular surgery within 8 weeks prior to C-Rex surgery\n* Preoperative IOP higher than 33 mmHg\n* Presence of a glaucoma type other than POAG\n* Presence of clinically significant intraocular pathology other than cataract or glaucoma","22 Years",{"count":324,"type":21},200,"12 Months","This study enrolls adults with primary open angle glaucoma (POAG) who underwent goniotomy intraocular pressure (IOP)-lowering surgery with the C-Rex Instrument. Patients are consented prior to surgery and followed for 12 months postoperatively. Data regarding IOP, use of glaucoma medications, and any device-related complications are collected during the study time period.",[28],[255,329,171,330],"Eye Diseases","Goniotomy","2025-03-19",{"date":333,"type":38},"2025-03-20",{"date":335,"type":38},"2024-08-14",{"date":286,"type":21},{"name":338,"class":45},"Iantrek, Inc.",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":347,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":94},"100576986","phase-4-a-study-investigating-oral-semaglutide-in-people-with-open-angle-glaucoma-100576986","NCT06792422","A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma","Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection","ABSALON","Inclusion Criteria:\n\n* Ability to read and speak Danish\n* 45 years or older at the time of inclusion\n* Visual acuity equal to or above 0.5 in the study eye\n* Diagnosis of POAG with MD ≤ 16 dB with repeatable and reliable (false positive less than 15 %) VF loss measured by standard automated perimetry on at least one eye\n* Receiving IOP-lowering glaucoma treatment\n* Nerve fiber layer defects identified by OCT\n\nExclusion Criteria:\n\n* Diabetes or renal impairment\n* Medical history of significant eye disease (including ocular trauma) other than glaucoma\n* Ocular inflammation\u002Finfection within three months from inclusion\n* Intraocular surgery 3 months before inclusion\n* Smoker at the time of inclusion\n* Pregnant or breast-feeding\n* Females of childbearing potential who are not using adequate contraceptive, which includes the following: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable; Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner; Sexual abstinence\n* Subjects allergic to drug ingredients administered during the trial\n* Subjects with untreated severe systemic disease or malignancies\n* Previous history of pancreatitis\n* BMI \\\u003C 18.5\n* Subjects receiving treatment with: Dipeptidyl peptidase-4 inhibitors; Other GLP-1RAs; Insulin; Insulin analogues; Sulfonylurea; Systemic corticosteroids; Immunosuppressants","45 Years",{"count":349,"type":21},126,[351],"PHASE4","The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner retinal function in patients with open-angle glaucoma as measured by the photopic negative response of the electroretinogram.\n\nResearchers will compare oral semaglutide to a placebo (a look-alike substance that contains no drug).\n\nParticipants will:\n\n* Take semaglutide or a placebo every day for 6 months.\n* Visit the clinic 5 times in total for tests and interviews: At baseline (the first day they are included in the study), after 1 month, after 2 months, after 3 months, and after 6 months (the last day they are included in the study).",[28,354,171],"Open-Angle Glaucoma",[171,356,357,199,358,359,360],"Semaglutide","Rybelsus","GLP-1RA","Photopic Negative Response","GLP-1","2025-01-20",{"date":363,"type":38},"2025-01-24",{"date":365,"type":21},"2025-01",{"date":367,"type":21},"2028-12",{"name":369,"class":93},"Glostrup University Hospital, Copenhagen",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":295,"sex":17,"minAge":18,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100480709","role-of-peripheral-vision-in-scene-perception-perisce-100480709","NCT05539508","Role of Peripheral Vision in Scene Perception (PERISCE)","Role of Peripheral Vision in Scene Perception","PERISCE","Inclusion Criteria:\n\nFor patients :\n\n* between 18 and 80 years old\n* stable bilateral primary open angle glaucoma (POAG)\n* visual acuity \\> 5\u002F10 for distant vision for the eye tested\n* peripheral visual field defect on the eye tested measured through a Humphrey Visual Field Analyzer\n\nFor healthy volunteers :\n\n* between 18 and 80 years old\n* visual acuity \\> 5\u002F10\n* absence of ophthalmologic disease other than Glaucoma (age-related macular degeneration, cataract except for uncomplicated cataract surgery, amblyopia, optic neuropathy, diabetic retinopathy …)\n\nExclusion Criteria:\n\n* ophthalmologic disease other than Glaucoma (age-related macular degeneration, cataract except for uncomplicated cataract surgery, amblyopia, optic neuropathy, diabetic retinopathy …)\n* treated with medication that might compromise sustained attention (benzodiazepine, narcoleptics)","80 Years",{"count":380,"type":21},120,"Despite its low spatial resolution, peripheral vision is very useful for rapidly categorizing a visual scene. Low spatial frequencies of a visual stimulus available in peripheral vision would allow a coarse categorization of the scene and objects (deciding, for example, whether it is an urban or natural landscape). This first representation would then trigger predictive mechanisms which would subsequently guide a more detailed visual analysis in central vision. The psychophysical studies that the investigators have already conducted in this scientific context has been carried out under normal vision conditions. The objective of this project is to study the influence of peripheral vision on central vision with an original approach: What are the consequences of a loss of peripheral vision on the processing performed in central vision? The project will concern patients with glaucoma. This ophthalmic pathology particularly affects the peripheral retina and thus represents a good pathological cognitive model of a visual recognition system in which peripheral vision is less important. The investigators will conduct psychophysical studies with glaucomatous patients and healthy volunteers with normal vision. All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. Participants will have to perform various tasks on these images using the keys on the keyboard.",[383],"Primary Open-angle Glaucoma (POAG)","2022-09-13",{"date":386,"type":38},"2022-09-14",{"date":388,"type":21},"2022-10-01",{"date":390,"type":21},"2027-07-01",{"name":392,"class":93},"University Hospital, Grenoble"]